# US 2015/0105535 A1 · Control of copolymer compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105535 A1
- Document ID: US20150105535A1
- Status: Published application
- Kind: A1
- Application number: 14/514,320
- Filed: 2014-10-14
- Published: 2015-04-16
- Earliest claimed: 2010-04-05
- Assignees: Momenta Pharmaceuticals, Inc.
- Applicants: Momenta Pharmaceuticals, Inc.
- Inventors: Claire Coleman; John Schaeck; Alicia Thompson
- Web page: https://patentgrep.com/patent/US20150105535A1

## CPC

- C07K 5/10: Tetrapeptides
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/001: {by chemical synthesis}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of making copolymers are described.

## Claims

### Claim 1

A method for preparing a composition comprising glatiramer acetate, the method comprising:
polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid protected L-lysine and L-tyrosine to generate a sample comprising intermediate-1;
treating the sample comprising intermediate-1 to partially depolymerize and deprotect benzyl-protected L-glutamic acid, thereby generating a sample comprising intermediate-2, wherein water is present for at least a portion of the treatment in a range of 4-25% weight/weight (w/w) against intermediate-1 present at the beginning of treatment;
treating the sample comprising intermediate-2 to deprotect trifluoroacetic acid protected L-lysine, thereby generating intermediate-3;
further processing the intermediate-3 to generate glatiramer acetate; and
purifying the glatiramer acetate to generate purified glatiramer acetate.
